Literature DB >> 12579406

Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.

Uri S Alon1, Roshanak Monzavi, Marc Lilien, Majid Rasoulpour, Mitchell E Geffner, Ora Yadin.   

Abstract

Hypertension has been anecdotally reported in children with familial hypophosphatemic rickets (XLH). To better identify and characterize the clinical and laboratory features of hypertensive XLH children, we reviewed the medical records of 41 XLH children, all treated with phosphate and vitamin D analogues. Eight children, who were originally normotensive, developed hypertension during the 2nd decade of life. At diagnosis of hypertension all had persistent secondary/tertiary hyperparathyroidism (HPTD), defined as high serum parathyroid hormone (PTH) for 12 months or longer. Seven had nephrocalcinosis (NC). Analysis of data showed that of 11 children with HPTD, 8 developed hypertension compared with 0 among 30 without HPTD (P<0.001). Of 40 children studied, 18 had NC that was significantly associated with both HPTD (P<0.01) and hypertension (P<0.025). At diagnosis of hypertension, serum calcium was elevated in 2. Plasma renin activity was high in 3 of 4 patients in whom it was measured. Doppler ultrasonography or renal scan was normal in the 5 children studied. Early echocardiography showed left ventricular hypertrophy in only 2 of 5 children studied. In 3 patients who underwent parathyroidectomy, hypertension persisted and 1 progressed to renal failure. Serum creatinine remained normal in all others. Successful treatment of hypertension consisted of beta-adrenergic blockers, angiotensin converting enzyme inhibitors, and Ca channel blockers as monotherapy or in combination. We conclude that hypertension in treated XLH children is closely associated with HPTD. Emphasis should therefore be placed on prevention of the development of HPTD as a complication of XLH treatment, and close monitoring for hypertension in those who do develop HPTD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579406     DOI: 10.1007/s00467-002-1044-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

Review 1.  Primary hyperparathyroidism: aggressive or conservative treatment?

Authors:  M Davies
Journal:  Clin Endocrinol (Oxf)       Date:  1992-04       Impact factor: 3.478

2.  NPT2a--the key to phosphate homeostasis.

Authors:  Henry M Kronenberg
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

3.  Cardiovascular abnormalities in patients with X-linked hypophosphatemia.

Authors:  R Nehgme; J T Fahey; C Smith; T O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

4.  Nephrocalcinosis and its relationship to treatment of hereditary rickets.

Authors:  P R Goodyer; J B Kronick; S Jequier; T M Reade; C R Scriver
Journal:  J Pediatr       Date:  1987-11       Impact factor: 4.406

5.  Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.

Authors:  C J Wu; Y M Song; W H Sheu
Journal:  Intern Med       Date:  2000-06       Impact factor: 1.271

6.  Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1996-10       Impact factor: 7.124

Review 7.  Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.

Authors:  S G Rostand; T B Drüeke
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

8.  Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years.

Authors:  G J Downing; J C Egelhoff; D K Daily; M K Thomas; U Alon
Journal:  J Pediatr       Date:  1992-04       Impact factor: 4.406

9.  Normal left ventricular performance in children with X-linked hypophosphatemic rickets: a Doppler echocardiography study.

Authors:  I Vered; Z Vered; J E Perez; A S Jaffe; M P Whyte
Journal:  J Bone Miner Res       Date:  1990-05       Impact factor: 6.741

Review 10.  Therapeutics of X-linked hypophosphatemic rickets.

Authors:  K Latta; S Hisano; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

View more
  20 in total

Review 1.  Familial hypophosphatemia: an unusual presentation with low back ache, heel pain, and a limp in a young man, and literature review.

Authors:  Sharon Arthur; Arvind Chopra
Journal:  Clin Rheumatol       Date:  2010-11-02       Impact factor: 2.980

Review 2.  Hypophosphatemic rickets: etiology, clinical features and treatment.

Authors:  Vito Pavone; Gianluca Testa; Salvatore Gioitta Iachino; Francesco Roberto Evola; Sergio Avondo; Giuseppe Sessa
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-06-24

Review 3.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

4.  Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients.

Authors:  Sean DeLacey; Ziyue Liu; Andrea Broyles; Sarah A El-Azab; Cristian F Guandique; Benjamin C James; Erik A Imel
Journal:  Bone       Date:  2019-07-02       Impact factor: 4.398

Review 5.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

6.  X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study.

Authors:  Louisa Bloudeau; Agnès Linglart; Sacha Flammier; Aurélie Portefaix; Aurélia Bertholet-Thomas; Sanaa Eddiry; Anna Barosi; Jean-Pierre Salles; Valérie Porquet-Bordes; Anya Rothenbuhler; Christelle Roger; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.714

7.  Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia.

Authors:  Olaya Hernández-Frías; Helena Gil-Peña; José M Pérez-Roldán; Susana González-Sanchez; Gema Ariceta; Sara Chocrón; Reyner Loza; Francisco de la Cerda Ojeda; Leire Madariaga; Inés Vergara; Marta Fernández-Fernández; Susana Ferrando-Monleón; Montserrat Antón-Gamero; Ángeles Fernández-Maseda; M Isabel Luis-Yanes; Fernando Santos
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

Review 8.  The enigma of hyperparathyroidism in hypophosphatemic rickets.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Pediatr Nephrol       Date:  2004-03-11       Impact factor: 3.714

Review 9.  Hypophosphatemic rickets due to perturbations in renal tubular function.

Authors:  Maria Goretti M G Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714

10.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

Authors:  Uri S Alon; Rachel Levy-Olomucki; Wayne V Moore; Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.